Corporate Update
Alvogen gets US FDA nod to market antiviral drug
Alvogen gets US FDA nod to market antiviral drug
![]()
By eHealth Network - 04 November 2017
US FDA has given a green signal to the marketing partner of Natco Pharma, Alvogen to market oseltamivir phosphate powder ”an antiviral medication used for the treatment of influenza virus types A and B in the body ” for oral suspension in the United States.
Natco Pharma said: “Alvogen has received final approval and is the first to market generic equivalent to oseltamivir phosphate, 6 mg/ml powder”.
The Chairman and CEO of Alvogen Robert Wessman, said: The approval and launch of Alvogens oseltamivir phosphate powder for oral suspension is great news for the US patients, who will have access to a more affordable alternative.
According to IMS Midas data, the annual sales for Oseltamivir suspension amount to the US $312 million in the U.S. market.
Currently, 75 products of Alvogen are in development and pending for FDA approvals for the U.S. market.
Like
Dislike
Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.
"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!
